IRIDEX Corporation (IRIX): Price and Financial Metrics


IRIDEX Corporation (IRIX): $2.25

-0.02 (-0.88%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

IRIX Stock Summary

  • With a market capitalization of $36,296,442, IRIDEX CORP has a greater market value than merely 10.5% of US stocks.
  • With a year-over-year growth in debt of -31.78%, IRIDEX CORP's debt growth rate surpasses just 9.94% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, IRIDEX CORP is reporting a growth rate of 199.39%; that's higher than 92.28% of US stocks.
  • If you're looking for stocks that are quantitatively similar to IRIDEX CORP, a group of peers worth examining would be NBRV, ISO, KVHI, TACT, and ICAD.
  • Visit IRIX's SEC page to see the company's official filings. To visit the company's web site, go to www.iridex.com.

IRIX Valuation Summary

  • In comparison to the median Healthcare stock, IRIX's price/sales ratio is 88.24% lower, now standing at 0.6.
  • IRIX's EV/EBIT ratio has moved up 10.8 over the prior 243 months.

Below are key valuation metrics over time for IRIX.

Stock Date P/S P/B P/E EV/EBIT
IRIX 2023-01-20 0.6 2 -4.1 -2.6
IRIX 2023-01-19 0.6 2 -4.0 -2.5
IRIX 2023-01-18 0.6 2 -4.1 -2.6
IRIX 2023-01-17 0.6 2 -4.0 -2.5
IRIX 2023-01-13 0.6 2 -4.0 -2.4
IRIX 2023-01-12 0.6 2 -4.0 -2.5

IRIX Growth Metrics

    Its year over year net income to common stockholders growth rate is now at 16.18%.
  • The 3 year net cashflow from operations growth rate now stands at 38.12%.
  • The 5 year cash and equivalents growth rate now stands at -53.31%.
IRIX's revenue has moved up $15,655,000 over the prior 49 months.

The table below shows IRIX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 57.031 -9.667 -8.842
2022-06-30 55.66 -8.205 -9.24
2022-03-31 55.331 -6.866 -5.606
2021-12-31 53.903 8.217 -5.225
2021-09-30 50.953 9.747 -2.961
2021-06-30 46.492 10.801 -2.515

IRIX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IRIX has a Quality Grade of B, ranking ahead of 78.49% of graded US stocks.
  • IRIX's asset turnover comes in at 1.188 -- ranking 15th of 186 Medical Equipment stocks.
  • STXS, FONR, and SMLR are the stocks whose asset turnover ratios are most correlated with IRIX.

The table below shows IRIX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-07-03 1.188 0.436 -0.221
2021-04-03 1.162 0.422 -0.575
2021-01-02 1.247 0.428 -0.493
2020-09-26 1.160 0.414 -0.559
2020-06-27 1.151 0.410 -0.513
2020-03-28 1.195 0.420 -0.474

IRIX Price Target

For more insight on analysts targets of IRIX, see our IRIX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.50 Average Broker Recommendation 1.25 (Strong Buy)

IRIX Stock Price Chart Interactive Chart >

Price chart for IRIX

IRIX Price/Volume Stats

Current price $2.25 52-week high $5.50
Prev. close $2.27 52-week low $1.96
Day low $2.18 Volume 12,000
Day high $2.27 Avg. volume 11,172
50-day MA $2.17 Dividend yield N/A
200-day MA $2.67 Market Cap 35.97M

IRIDEX Corporation (IRIX) Company Bio


IRIDEX Corporation develops, manufactures, markets, sells, and services medical laser systems and associated instrumentation for the treatment of the sight-threatening eye diseases. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. The company was founded in 1989 and is based in Mountain View, California.


IRIX Latest News Stream


Event/Time News Detail
Loading, please wait...

IRIX Latest Social Stream


Loading social stream, please wait...

View Full IRIX Social Stream

Latest IRIX News From Around the Web

Below are the latest news stories about IRIDEX CORP that investors may wish to consider to help them evaluate IRIX as an investment opportunity.

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022

Achieves Record Quarterly Glaucoma Probe sales and 6% Full Year Revenue Growth Achieves Record Quarterly Glaucoma Probe sales and 6% Full Year Revenue Growth

GlobeNewswire | January 10, 2023

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022

Achieves Record Quarterly Glaucoma Probe sales and 6% Full Year Revenue GrowthMOUNTAIN VIEW, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today provided preliminary unaudited operational and financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 Results Total revenue is expected to be between $15.1 millio

Yahoo | January 10, 2023

Iridex Earnings Perspective: Return On Capital Employed

According to Benzinga Pro data, during Q3, Iridex (NASDAQ: IRIX ) posted sales of $14.63 million. Earnings were up 21.15%, but Iridex still reported an overall loss of $1.77 million. Iridex collected $13.76 million in revenue during Q2, but reported earnings showed a $2.24 million loss. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and … Full story available on Benzinga.com

Benzinga | December 21, 2022

Iridex to Participate in Fireside Chat with Stifel Equity Research

MOUNTAIN VIEW, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in a fireside chat with its covering equity research analyst from Stifel. Management is scheduled to discuss the business on Thursday, December 8, 2022 at 9:00 a.m. PT / 12:00 p.m. ET. A live and archived webcast of the event will be availabl

Yahoo | December 6, 2022

IRIDEX Third Quarter 2022 Earnings: Beats Expectations

IRIDEX ( NASDAQ:IRIX ) Third Quarter 2022 Results Key Financial Results Revenue: US$14.6m (up 10% from 3Q 2021). Net...

Yahoo | November 13, 2022

Read More 'IRIX' Stories Here

IRIX Price Returns

1-mo 7.14%
3-mo -0.88%
6-mo -25.00%
1-year -55.88%
3-year -17.58%
5-year -69.55%
YTD 11.94%
2022 -67.10%
2021 143.43%
2020 12.56%
2019 -52.55%
2018 -38.32%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7278 seconds.